Fierce Pharma Fierce Biotech Fierce Healthcare Fierce Life Sciences Events Advertise About Us Pharma Vaccines Asia Cell & Gene Therapy Drug Delivery Executives Manufacturing Facilities Recalls Warning Letters Marketing Special Reports Fierce 50 Special Report Awards Gala Trending Oncology Supply Chain AI and Machine Learning Awards Outsourcing Awards Innovation Awards Pharma Marketing Awards Resources Podcasts Fierce Events Industry Events Webinars Whitepapers Survey Events Subscribe Subscribe Pharma Vaccines Asia Cell & Gene Therapy Drug Delivery Executives Manufacturing Facilities Recalls Warning Letters Marketing Special Reports Fierce 50 Special Report Awards Gala Trending Oncology Supply Chain AI and Machine Learning Awards Outsourcing Awards Innovation Awards Pharma Marketing Awards Resources Podcasts Fierce Events Industry Events Webinars Whitepapers Survey Events Subscribe Fierce Pharma Fierce Biotech Fierce Healthcare Fierce Life Sciences Events Advertise About Us Pharma NICE looks askance at UCB's Cimzia By Tracy Staton Oct 20, 2009 11:24am Pharma U.K. cost-effectiveness watchdog NICE says it's "minded not to recommended" the UCB drug Cimzia as a treatment option for rheumatoid arthritis, citing uncertainty embedded in economic models submitted by the company. Report Pharma
